Investor Alert

July 2, 2020, 5:19 a.m. EDT

Diabetic Lancing Device Market Future Demand Status, Global Industry Revenue of Top Key Players, Industry Share and Manufacturing Size | COVID-19 Impact Forecast by 2020-2027

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jul 02, 2020 (Profound via COMTEX) -- Diabetes is a global epidemic affecting an estimated 382 million people worldwide. The WHO projects that diabetes will be the 7th leading cause of death by 2030. An estimated 4 million people die annually from the complications associated with diabetes. Therefore, if the current trend associated with the prevalence of diabetes continues over the coming years, the number of diabetic patients across the globe would be tremendous after a decade. Increasing prevalence of diabetes will result in the rising demand for devices and products to monitor and control diabetes, eventually leading to increased consumption of lancets. Thus, the demand for lancets is expected to be enormous in the coming future.

Download Sample - https://www.novaoneadvisor.com/report/sample/2328

Lancets are one of the widely used alternative device to obtain the blood samples. These devices are receiving global recognition and acceptance due to its several convenient characteristics which gives them an edge over the traditional methods for vein puncture. Some of the important features of the safety lancets are painless vein puncture, easy handling, and safety while using. The major applications of the lancets are HIV screening test, capillary blood micro sampling and cholesterol test, blood group test, coagulation tests, haemoglobin, allergy tests, and many other blood based tests. According to the International Diabetes Federation (IDF), approximately 29.2 million people in the US are estimated suffer from diabetes in 2015. Japan had approximately 7.2 million. in 2015.

The global diabetic lancing devices market is segmented on the basis of type, gauge, penetration depth, and end user.

On the basis of type, the market for diabetic lancing devices it is segmented into safety lancets and standard lancets. The safety lancets are further categorized into push-button safety lancets, pressure activated safety lancets, and side button safety lancets. The pen needles is further categorized into standard pen needles and safety pen needles.

On the basis of gauge, the market for diabetic lancing devices it is segmented into 17/18g, 21g, 23g, 25g, 28g, 30g, and others.

On the basis of penetration depth, the market for diabetic lancing devices it is segmented into 0.8 mm to 1.0 mm, 1.1 mm to 1.5 mm, 1.6 mm to 2.0 mm, 2.1 mm to 2.5 mm, 2.5 mm to 3.0 mm, and others.

On the basis of the end users, it is segmented into hospitals amp; clinics, diagnostic centers amp; medical institutions, home care amp; home diagnostics, research amp; academic laboratories, and others.

Key Players:

Some of the key players in the global diabetic lancing devices market are B. Braun Melsungen AG, Terumo Corporation, Becton Dickinson, Sanofi, F. Hoffmann-La Roche AG, Bayer AG, Novo Nordisk A S, Eli Lilly and Company, Owen Mumford Ltd, Medtronic, Ypsomed Holding AG, Sarstedt AG amp; Co, Greiner Bio One, Abbott Laboratories, HTL-STREFA S.A, Improve Medical, UltiMed, Inc., Allison Medical, Inc., Artsana S.p.a., VOGT MEDICAL, Perrigo Diabetes Care, MedExel Co., Ltd, ARKRAY Inc., Simple Diagnostics, Stat Medical, Terumo, Trividia Health, and others.

Download Full Report - https://www.novaoneadvisor.com/report/checkout/2328

PDF File Dispatch Time - 24 Hours. We Will also support Word, PPT, Excel Files Dispatch

Contact Us:

Nova One Advisor

URL - https://www.novaoneadvisor.com/

Mailing Address: 237 West 35th Street,Suite 605,New York, NY 10001, USA

Any Assistance, Email ndash; sales@novaoneadvisor.com


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.